Blache Ulrich, Ehrbar Martin
Department of Obstetrics, University and University Hospital Zurich, Zurich, Switzerland.
Department of Health Sciences and Technology, Institute for Biomechanics, ETH Zurich, Zurich, Switzerland.
Adv Wound Care (New Rochelle). 2018 Jul 1;7(7):232-246. doi: 10.1089/wound.2017.0760.
Diseases related to vascular malfunction, hyper-vascularization, or lack of vascularization are among the leading causes of morbidity and mortality. Engineered, vascularized tissues as well as angiogenic growth factor-releasing hydrogels could replace defective tissues. Further, treatments and testing of novel vascular therapeutics will benefit significantly from models that allow for the study of vascularized tissues under physiological relevant conditions. Inspired by fibrin, the provisional matrix during wound healing, naturally derived and synthetic hydrogel scaffolds have been developed for vascular engineering. Today, engineers and biologists use commercially available hydrogels to pre-vascularize tissues, to control the delivery of angiogenic growth factors, and to establish vascular diseases models. For clinical translation, pre-vascularized tissue constructs must be sufficiently large and stable to substitute function-relevant tissue defects and integrate with host vascular perfusion. Moreover, the continuous integration of knowhow from basic vascular biology with innovative, tailorable materials and advanced manufacturing technologies is key to achieving near-physiological tissue models and new treatments to control vascularization. For transplantation, engineered tissues must comprise hierarchically organized vascular trees of different caliber and function. The development of novel vascularization-promoting or -inhibiting therapeutics will benefit from physiologically relevant vessel models. In addition, tissue models representing treatment-relevant vascular tissue functions will increase the capacity to screen for therapeutic compounds and will significantly reduce the need for animals for their validation.
与血管功能障碍、血管过度增生或血管生成不足相关的疾病是发病和死亡的主要原因之一。工程化的血管化组织以及释放血管生成生长因子的水凝胶可以替代有缺陷的组织。此外,新型血管治疗方法的治疗和测试将从能够在生理相关条件下研究血管化组织的模型中显著受益。受伤口愈合过程中的临时基质纤维蛋白的启发,已经开发出天然衍生和合成的水凝胶支架用于血管工程。如今,工程师和生物学家使用市售水凝胶对组织进行预血管化、控制血管生成生长因子的递送并建立血管疾病模型。对于临床转化,预血管化组织构建体必须足够大且稳定,以替代功能相关的组织缺陷并与宿主血管灌注整合。此外,将基础血管生物学的专业知识与创新的、可定制的材料和先进的制造技术持续整合,是实现接近生理状态的组织模型和控制血管生成的新治疗方法的关键。对于移植,工程化组织必须包含不同口径和功能的分层组织的血管树。新型促进或抑制血管生成治疗方法的开发将受益于生理相关的血管模型。此外,代表与治疗相关的血管组织功能的组织模型将提高筛选治疗化合物的能力,并将显著减少用于验证的动物需求。